Therapeutic Asset Ratings
13,155 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Nivolumab
Diffuse Large B-Cell Lymphoma Of The Central Nervous System
National Cancer Institute (NCI)
P2
B
(60)
Nivolumab
Prostate Disorder
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
P2
B
(60)
Nivolumab
Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
P2
B
(60)
Nivolumab
Angioimmunoblastic T-Cell Lymphoma
Mayo Clinic
P2
B
(60)
Nivolumab
Burkitt Lymphoma
National Cancer Institute (NCI)
P2
B
(60)
Nivolumab
Mycosis Fungoides
National Cancer Institute (NCI)
P2
B
(60)
Nivolumab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Mayo Clinic
P2
B
(60)
Nivolumab
Skin Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
P2
B
(60)
Nivolumab
T-Cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Bengbu Medical University
P2
B
(60)
Nivolumab
Richter Transformation
Northwestern University
P2
B
(60)
Nivolumab
Smoldering Plasma Cell Myeloma
Massachusetts General Hospital
P2
B
(60)
Nivolumab
Neoplasm
Boehringer Ingelheim
P2
B
(60)
Nivolumab
Ureter Cancer
M.D. Anderson Cancer Center
P2
B
(60)
Nivolumab
Urethra Cancer
M.D. Anderson Cancer Center
P2
B
(60)
Nivolumab
Ulcerative Colitis
Diwakar Davar
P2
B
(60)
Nivolumab
Renal Pelvis/Ureter Urothelial Carcinoma
Nagoya University
P2
B
(60)
Nogitecan
Essential Thrombocythemia
National Cancer Institute (NCI)
P2
B
(60)
Nogitecan
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P2
B
(60)
Nogitecan
Acquired Polycythemia Vera
National Cancer Institute (NCI)
P2
B
(60)
Nogitecan
Rhabdoid Tumor
Pfizer
P2
B
(60)
Ny-Eso-1 Peptide Vaccine
Ovarian Carcinoma
Georgetown University
P2
B
(60)
Obinutuzumab
Aggressive B-Cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(60)
Obinutuzumab
Nodal Marginal Zone B-Cell Lymphoma
Mayo Clinic
P2
B
(60)
Obinutuzumab
T-Cell/Histiocyte Rich Large B Cell Lymphoma
National Cancer Institute (NCI)
P2
B
(60)
Olaparib
Hereditary Breast Carcinoma
Okayama University
P2
B
(60)
Showing 2001 to 2025 of 13,155 assets
Previous
Page 81 of 527
Next